Last reviewed · How we verify
18F-2-fluoro-2-deoxy-D-glucose
18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection.
18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection. Used for PET imaging of malignant neoplasms (oncology), PET imaging of brain disorders (dementia, epilepsy), PET imaging of cardiac viability assessment.
At a glance
| Generic name | 18F-2-fluoro-2-deoxy-D-glucose |
|---|---|
| Sponsor | Eastern Health, Canada |
| Drug class | Positron emission tomography (PET) imaging agent |
| Target | Glucose transporter (GLUT1) and hexokinase |
| Modality | Small molecule |
| Therapeutic area | Oncology, Neurology, Cardiology |
| Phase | Phase 3 |
Mechanism of action
18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) is taken up by cells with high glucose metabolism, particularly cancer cells and inflamed tissues. The fluorine-18 isotope undergoes positron decay, allowing detection via positron emission tomography (PET) imaging. This enables visualization and localization of metabolically active lesions for diagnostic and staging purposes.
Approved indications
- PET imaging of malignant neoplasms (oncology)
- PET imaging of brain disorders (dementia, epilepsy)
- PET imaging of cardiac viability assessment
Common side effects
- Radiation exposure
- Allergic reaction to tracer
- Injection site reactions
Key clinical trials
- Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (PHASE1)
- Detection of Brown Adipose Tissue by Magnetic Resonance Imaging
- Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis (NA)
- Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery (NA)
- Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors (PHASE2)
- Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy (NA)
- Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases (PHASE2)
- Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-2-fluoro-2-deoxy-D-glucose CI brief — competitive landscape report
- 18F-2-fluoro-2-deoxy-D-glucose updates RSS · CI watch RSS
- Eastern Health, Canada portfolio CI